Drug intelligence / Profile preview

AC-(D)PHE-PRO-BOROHOMOLYS-OH

Development stage: Unknown
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules

Overview

AC-(D)PHE-PRO-BOROHOMOLYS-OH is an experimental small molecule dipeptide containing a boronic acid moiety. Its structure includes an N-acetylated D-phenylalanine, proline, and a borohomolysine residue. The compound acts as a prothrombin inhibitor, suggesting anticoagulant properties by targeting the coagulation cascade at the level of prothrombin (factor II). It has not been approved for clinical use and is primarily studied in preclinical or early research settings[1][2][3].

Other names: AC-(D)PHE-PRO-BOROHOMOLYS-OH

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on AC-(D)PHE-PRO-BOROHOMOLYS-OH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC-(D)PHE-PRO-BOROHOMOLYS-OH.

Explore the full profile